AU2018252974B2 - Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 - Google Patents
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 Download PDFInfo
- Publication number
- AU2018252974B2 AU2018252974B2 AU2018252974A AU2018252974A AU2018252974B2 AU 2018252974 B2 AU2018252974 B2 AU 2018252974B2 AU 2018252974 A AU2018252974 A AU 2018252974A AU 2018252974 A AU2018252974 A AU 2018252974A AU 2018252974 B2 AU2018252974 B2 AU 2018252974B2
- Authority
- AU
- Australia
- Prior art keywords
- ser
- gly
- seq
- thr
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024220214A AU2024220214A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| AU2024220212A AU2024220212A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| US62/485,077 | 2017-04-13 | ||
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024220214A Division AU2024220214A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| AU2024220212A Division AU2024220212A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018252974A1 AU2018252974A1 (en) | 2019-11-28 |
| AU2018252974B2 true AU2018252974B2 (en) | 2024-10-17 |
Family
ID=61911717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018252974A Active AU2018252974B2 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| AU2024220214A Pending AU2024220214A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| AU2024220212A Pending AU2024220212A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024220214A Pending AU2024220214A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| AU2024220212A Pending AU2024220212A1 (en) | 2017-04-13 | 2024-09-30 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11708415B2 (https=) |
| EP (3) | EP4549586A3 (https=) |
| JP (3) | JP7321939B2 (https=) |
| KR (2) | KR102605045B1 (https=) |
| CN (2) | CN110431240B (https=) |
| AU (3) | AU2018252974B2 (https=) |
| CA (1) | CA3059350A1 (https=) |
| ES (1) | ES3052989T3 (https=) |
| IL (2) | IL314591A (https=) |
| MX (2) | MX2019012171A (https=) |
| SG (1) | SG11201909457XA (https=) |
| WO (1) | WO2018190990A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012171A (es) * | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7165618B2 (ja) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | アレルギー性鼻炎のリスクを判定する方法 |
| US20210000949A1 (en) * | 2019-05-01 | 2021-01-07 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| CA3236201A1 (en) * | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33) |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (zh) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | 用于治疗人类和非-人类灵长类中哮喘的方法和组合物 |
| FR2900817B1 (fr) * | 2006-05-12 | 2008-12-19 | Gambro Lundia Ab | Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient |
| CN1896275B (zh) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101600456A (zh) * | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US8367333B2 (en) | 2008-12-12 | 2013-02-05 | Decode Genetics Ehf. | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| EP2678358B1 (en) | 2011-02-23 | 2015-07-22 | F.Hoffmann-La Roche Ag | Antibodies against human il33r and uses thereof |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| WO2014090800A1 (en) * | 2012-12-10 | 2014-06-19 | Vib Vzw | Novel interleukin-33 inhibitors |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EP2968454B1 (en) * | 2013-03-15 | 2019-02-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| EP3088517B1 (en) | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| ES2866935T3 (es) | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA2943326A1 (en) * | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
| NO2785538T3 (https=) | 2014-05-07 | 2018-08-04 | ||
| CR20170240A (es) | 2014-11-10 | 2018-04-03 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos |
| JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Ｉｌ－３３媒介性障害のための治療及び診断方法 |
| AU2015346150B2 (en) | 2014-11-14 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
| CN104531689A (zh) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用 |
| HRP20210096T1 (hr) | 2015-03-31 | 2021-03-05 | Medimmune Limited | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| MX2019012171A (es) * | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
-
2018
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/es unknown
- 2018-03-20 EP EP25162154.6A patent/EP4549586A3/en active Pending
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 IL IL314591A patent/IL314591A/en unknown
- 2018-03-20 CN CN201880018649.2A patent/CN110431240B/zh active Active
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en not_active Ceased
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/ja active Active
- 2018-03-20 AU AU2018252974A patent/AU2018252974B2/en active Active
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 IL IL269873A patent/IL269873B2/en unknown
- 2018-03-20 ES ES21162316T patent/ES3052989T3/es active Active
- 2018-03-20 CN CN202610146824.2A patent/CN121951033A/zh active Pending
- 2018-03-20 EP EP21162316.0A patent/EP3957752B1/en active Active
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/ko active Active
- 2018-03-20 KR KR1020237039438A patent/KR102751957B1/ko active Active
-
2019
- 2019-10-10 MX MX2024002689A patent/MX2024002689A/es unknown
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-06-07 US US18/330,736 patent/US12612462B2/en active Active
- 2023-07-26 JP JP2023121229A patent/JP7557581B2/ja active Active
-
2024
- 2024-09-13 JP JP2024158740A patent/JP2024163308A/ja active Pending
- 2024-09-30 AU AU2024220214A patent/AU2024220214A1/en active Pending
- 2024-09-30 AU AU2024220212A patent/AU2024220212A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018252974B2 (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 | |
| KR102645242B1 (ko) | 염증 질환의 치료 방법 | |
| AU2016333903B2 (en) | Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof | |
| CN113874073A (zh) | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 | |
| TW202348249A (zh) | 使用c5a活性抑制劑於發炎性疾病之治療 | |
| EA031745B1 (ru) | Антитела анти-il-33 и их применение | |
| KR20190075133A (ko) | 렙틴 수용체에 길항하는 항원-결합 단백질 | |
| RU2776241C2 (ru) | Лечение и ингибирование воспалительных заболеваний легких у пациентов с аллелями риска в генах, кодирующих il33 и il1rl1 | |
| HK40069286B (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 | |
| HK40069286A (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |